Needham & Company
-
Mereo BioPharma to Participate in Fireside Chat at the 22nd Annual Needham Healthcare Conference
-
Mereo BioPharma to Participate in Fireside Chat at the 22nd Annual Needham Healthcare Conference
-
UPDATE: Mereo BipPharma Group (MREO) PT Lowered to $5 at Needham & Company
-
Needham & Company Reiterates Buy Rating, $10 Price Target on Mereo BipPharma Group (MREO)
-
Mereo BioPharma to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference
-
Mereo BioPharma to Participate in Fireside Chat at the 21st Annual Needham Virtual Healthcare Conference
-
Needham & Company Reiterates Buy Rating on Mereo BipPharma Group (MREO)
-
Mereo's (MREO) Alvelestat's Excellent Tolerability and Ease of Administration Highlight Potential in Multiple Indications - Needham
-
Mereo BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference
-
Mereo BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference
-
Mereo BioPharma Reports Full Year 2020 Financial Results and Recent Highlights
-
Mereo BioPharma Reports Full Year 2020 Financial Results and Recent Highlights
-
Mereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
-
Mereo BioPharma Group plc Announces Closing of Public Offering of American Depositary Shares and Full Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
-
Mereo BioPharma Group plc Announces Pricing of Public Offering of American Depositary Shares
-
Mereo BioPharma Group plc Announces Pricing of Public Offering of American Depositary Shares
-
Mereo BioPharma (MREO) Announces Proposed Public Offering of American Depositary Shares
-
Mereo BioPharma Group plc Announces Proposed Public Offering of American Depositary Shares
-
Mereo BioPharma Group plc Announces Proposed Public Offering of American Depositary Shares

